Regeneronreason 04 of 4it is wired into how the customer already worksderived 2026-09-08accession 0000872589-26-000025
Our VelocImmune technology, other antibody generation technologies, and late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companies
Many of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery system
Product candidates in Phase 2 and Phase 3 clinical development include fianlimab, odronextamab, linvoseltamab, itepekimab, pozelimab + cemdisiran, and olatorepatide
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedfour sentences · whole, uncut
the claims it rests on
“Our VelocImmune technology, other antibody generation technologies, and late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companies”
“Many of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery system”
“Product candidates in Phase 2 and Phase 3 clinical development include fianlimab, odronextamab, linvoseltamab, itepekimab, pozelimab + cemdisiran, and olatorepatide”
what it was checked against
EYLEA HD pre-filled syringe pursuit
“While the FDA recently approved EYLEA HD for the treatment of RVO and for additional dosing regimens and we continue to work toward FDA approval of the EYLEA HD pre-filled syringe as discussed under Part I, Item 2.”